Key Highlights

  • Adjusted EPS of USD 4.10 beat the consensus estimate of USD 4.00, while GAAP diluted EPS was USD 0.82.
  • Reported Revenue of USD 1.767 billion topped the consensus estimate of USD 1.75 billion, with organic revenue up 9%.
  • Full year revenue guidance rose USD 43 million at the midpoint, with adjusted EPS guided to USD 14.60 to 14.70.
  • The company announced the Acquisition of MOBILion Systems, adding high resolution ion mobility technology to its mass spectrometry portfolio.

Waters Corporation (NYSE:WAT) reported third quarter 2026 revenue of USD 1.767 billion, above the consensus estimate of USD 1.75 billion and up from USD 800 million a year earlier, before the Biosciences and Diagnostic Solutions acquisition. The total comprised USD 871 million of organic revenue and USD 896 million from the acquired businesses. Adjusted EPS of USD 4.10 grew 21% from USD 3.40 and exceeded the consensus estimate of USD 4.00. GAAP diluted EPS was USD 0.82 versus USD 2.50 a year earlier, as purchased intangibles amortization rose to USD 244 million from USD 12 million and Net Income fell to USD 81 million from USD 149 million.

Instruments and Consumables Lead Organic Growth

Organic revenue rose 9% as reported and 10% in constant currency. The Analytical Sciences Division grew 8% to USD 703 million, with double digit instrument and chemistry growth. Biosciences Division revenue was USD 396 million against USD 387 million on a prior year comparable basis, with reagents up high single digits. The Advanced Diagnostics Division contributed USD 500 million from Diagnostic Solutions and USD 75 million from the Clinical business, and the Materials Sciences Division reached USD 93 million from USD 87 million. Adjusted Operating Margin was 30.1% versus 30.3% a year earlier. Chief Executive Officer Dr. Udit Batra credited consumables growth, double digit constant currency growth in LC-MS instruments, and Demand tied to GLP-1s, PFAS and India generics, and said synergy and integration commitments for the acquired businesses are ahead of schedule.

Every Component of 2026 Guidance Was Raised

Total reported revenue for 2026 is guided to USD 6.479 billion to USD 6.497 billion, organic constant currency growth to 9.1% to 9.7%, and adjusted EPS to USD 14.60 to 14.70, up 11% to 12% from the prior year. Fourth quarter guidance calls for total revenue of USD 1.801 billion to USD 1.819 billion, including about USD 817 million from acquired businesses, organic constant currency growth of 7.0% to 9.0% and adjusted EPS of USD 4.58 to 4.68, up 1% to 3%. Adjusted EPS guidance carries no GAAP reconciliation because acquisition related amortization, restructuring and legal costs cannot be forecast with precision and could be significant.

Fourth Quarter Guidance, Cash and Debt Against Third Quarter Actuals

Fourth quarter adjusted EPS guidance of USD 4.58 to 4.68 compares with USD 4.10 in the third quarter, and revenue guidance of USD 1.801 billion to USD 1.819 billion compares with USD 1.767 billion. Operating Cash Flow was USD 98 million against USD 187 million a year earlier, and adjusted free cash flow was USD 68 million against USD 160 million after USD 43 million of Capital spending. Notes payable and debt stood at USD 5.133 billion against USD 1.407 billion at year end 2025, with cash of USD 593 million, while net interest expense rose to USD 53 million from USD 22 million. The MOBILion Systems acquisition adds ion mobility separation technology to the mass spectrometry portfolio.